LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 748 | 4156 | 0.1800 | -0.1669 |
| MCF7 | PF477736 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 1458 | 4156 | 0.3508 | 0.0762 |
| MCF7 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 725 | 4156 | 0.1744 | -0.1747 |
| MCF7 | PHA-665752 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 3029 | 4156 | 0.7289 | 0.6142 |
| MCF7 | PHA-793887 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 639 | 4156 | 0.1538 | -0.2041 |
| MCF7 | PI103 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1057 | 4156 | 0.2545 | -0.0608 |
| MCF7 | PLX-4720 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 2141 | 4156 | 0.5151 | 0.3101 |
| MCF7 | QL-X-138 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1078 | 4156 | 0.2595 | -0.0537 |
| MCF7 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1019 | 4156 | 0.2453 | -0.0739 |
| MCF7 | Radicicol | 10.0 | uM | LJP5 | 72 | hr | 1235 | 998 | 4156 | 0.2403 | -0.0810 |
| MCF7 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1235 | 947 | 4156 | 0.2280 | -0.0985 |
| MCF7 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 706 | 4156 | 0.1699 | -0.1813 |
| MCF7 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 3184 | 4156 | 0.7661 | 0.6672 |
| MCF7 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 2690 | 4156 | 0.6473 | 0.4981 |
| MCF7 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1703 | 4156 | 0.4098 | 0.1602 |
| MCF7 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1235 | 2601 | 4156 | 0.6258 | 0.4676 |
| MCF7 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1235 | 2605 | 4156 | 0.6269 | 0.4690 |
| MCF7 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1645 | 4156 | 0.3960 | 0.1405 |
| MCF7 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 1576 | 4156 | 0.3792 | 0.1166 |
| MCF7 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 649 | 4156 | 0.1562 | -0.2007 |
| MCF7 | TGX221 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 3775 | 4156 | 0.9084 | 0.8696 |
| MCF7 | Torin1 | 10.0 | uM | LJP6 | 72 | hr | 1235 | 1138 | 4156 | 0.2739 | -0.0332 |
| MCF7 | Torin2 | 10.0 | uM | LJP5 | 72 | hr | 1235 | 943 | 4156 | 0.2271 | -0.0999 |
| MCF7 | Tozasertib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 1318 | 4156 | 0.3173 | 0.0285 |
| MCF7 | Trametinib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 2379 | 4156 | 0.5726 | 0.3918 |